{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:31:02Z","timestamp":1785493862445,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejphar.2018.09.014","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:21:06Z","timestamp":1536322866000},"page":"85-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects"],"prefix":"10.1016","volume":"838","author":[{"given":"Mara","family":"Gavazzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Mario","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vizzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Gorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-3454","authenticated-orcid":false,"given":"Edoardo","family":"Sciatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Raddino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.09.014_bib1","first-page":"2167","article-title":"Assessing endothelial vasodilator function with the Endo-PAT 2000","volume":"44","author":"Axtell","year":"2010","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejphar.2018.09.014_bib2","first-page":"1","article-title":"Standardization of left atrial, right ventricular, and right atrial deformation imaging using twodimensional speckle tracking echocardiography: a consensus document of the EACVI\/ase\/industry task force to standardize deformation imaging","volume":"0","author":"Badano","year":"2018","journal-title":"Eur. Heart J. - Cardiovasc. Imaging"},{"issue":"11","key":"10.1016\/j.ejphar.2018.09.014_bib3","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"Bonetti","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.09.014_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"issue":"5\u20136","key":"10.1016\/j.ejphar.2018.09.014_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ejphar.2018.09.014_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"ENDEAVOR Investigators.Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicenter study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: from marvel to menace","volume":"113","author":"Forstermann","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.09.014_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib10","doi-asserted-by":"crossref","first-page":"138e144","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J. Card. Fail."},{"issue":"19","key":"10.1016\/j.ejphar.2018.09.014_bib11","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1161\/CIRCULATIONAHA.107.748574","article-title":"Cross-sectional relations of digital vascular function to cardiovascular risk factors in the framingham heart study","volume":"117","author":"Hamburg","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2018.09.014_bib12","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: Part 2: prevention, treatment, guidelines, and future directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ejphar.2018.09.014_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/01.RES.0000264500.11888.f0","article-title":"Ubiquitin and ubiquitin-like proteins in protein regulation","volume":"100","author":"Herrmann","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2018.09.014_bib14","unstructured":"https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm, 2009. National Cancer Institute Cancer Therapy Evaluation Program (CTEP). Common Toxicity Criteria for Adverse Eventsv4.03 (CTCAE)."},{"issue":"1","key":"10.1016\/j.ejphar.2018.09.014_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"5","key":"10.1016\/j.ejphar.2018.09.014_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jpeds.2009.04.060","article-title":"Impaired vascular function in obese adolescents with insulin resistance","volume":"155","author":"Mahmud","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejphar.2018.09.014_bib17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.freeradbiomed.2006.03.003","article-title":"Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells","volume":"40","author":"Meiners","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2018.09.014_bib18","first-page":"210:32","article-title":"Effect of breast cancer cardiotoxic drugs on left atrial myocardium mechanics. Searching for an early cardiotoxicity marker","author":"Moreno","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"8","key":"10.1016\/j.ejphar.2018.09.014_bib20","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.09.014_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur. J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ejphar.2018.09.014_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2007.11.044","article-title":"Prognostic role of flow-mediated dilation and cardiac risk factors in postmenopausal women","volume":"51","author":"Origliani","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCULATIONAHA.106.649863","article-title":"The bitter end: the ubiquitin\u2013 proteasome system and cardiac dysfunction","volume":"115","author":"Patterson","year":"2007","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ejphar.2018.09.014_bib24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.109.904557","article-title":"Ubiqukin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies","volume":"121","author":"Predmore","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejphar.2018.09.014_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfus. Apher. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2018.09.014_bib26","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2018.09.014_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehq010","article-title":"Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events","author":"Rubinshtein","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2018.09.014_bib28","doi-asserted-by":"crossref","unstructured":"Russell, S.D., Lyon, A., Lenihan, D.J., Moreau, P., Joshua, D., Chang, W.L., Palumbo, A., Goldschmidt, H., H\u00e1jek, R., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, E., Rosi\u00f1ol, L., et al., 2015. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866), ASH 2015 Annual Meeting Abstract 4250.","DOI":"10.1182\/blood.V126.23.4250.4250"},{"issue":"9","key":"10.1016\/j.ejphar.2018.09.014_bib29","first-page":"637","article-title":"Uncontrolled type 1 diabetes mellitus and endothelial dysfunction in adolescents","volume":"9","author":"Shachor-Meyouhas","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"issue":"4","key":"10.1016\/j.ejphar.2018.09.014_bib30","first-page":"505","article-title":"Adverse effects of corticosteroids on the cardiovascular system","volume":"16","author":"Sholter","year":"2000","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case\u2013control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2018.09.014_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1096\/fj.03-0054com","article-title":"Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin\u2013proteasome pathway","volume":"18","author":"Stangl","year":"2004","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.ejphar.2018.09.014_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.09.014_bib34","doi-asserted-by":"crossref","first-page":"48309","DOI":"10.1074\/jbc.M107146200","article-title":"Sarco\/endoplasmic reticulum calcium ATPase-2 expression is regulated by ATF6 during the endoplasmic reticulum stress response: intracellular signaling of calcium stress in a cardiac myocyte model system","volume":"276","author":"Thuerauf","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.09.014_bib35","first-page":"330","article-title":"A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma","volume":"6","author":"Van de Donk","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejphar.2018.09.014_bib36","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/CIRCULATIONAHA.106.684795","article-title":"Proteasome-dependent degradation of guanosine 50- triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus","volume":"116","author":"Xu","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.09.014_bib37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2018.09.014_bib38","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918305314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918305314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:50:26Z","timestamp":1571856626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918305314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"alternative-id":["S0014299918305314"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}